Meanwhile, there was bad blood between cell therapy players and their investors.
Investors got jittery on Friday, and for good reason: like all allogeneic cell therapy players Adicet is seeing patients relapse.
In oncology settings outside multiple myeloma investors have picked two early winners.
It is hard to see a combination of the two businesses as much beyond a defensive move in troubled times.
Recently unveiled abstract titles for next month's SITC conference reveal new competition for Incyte’s small-molecule PD-L1 inhibitors.
Asset prices fall sufficiently to persuade Roche to sign up to Poseida’s allogeneic cell therapies.